Tuesday, June 5, 12:00-2:00 p.m., Dr. Lawrence Hookey to present “A Randomized, Assessor-Blinded, Multicenter Study Demonstrates the Efficacy and Safety…
rAd-IFN/Syn3, a novel gene therapy, is in Phase 3 development to treat high-grade non-muscle invasive bladder cancer patients, who…
• Rebiotix’s RBX2660 is a non-antibiotic treatment in Phase 3 development for the prevention of recurrent Clostridium difficile infection (CDI)…
First and only FDA-Approved, Ready-to-Drink Low-Volume Bowel Prep Parsippany, NJ – February 12, 2018 – Ferring Pharmaceuticals Inc. announced today…
Ferring Expands U.S. Endocrinology Portfolio PARSIPPANY, N.J., January 31, 2018 – Ferring Pharmaceuticals Inc. today announced that the U.S. Food…
New Ready-to-Drink Low-Volume Colonoscopy Prep in a Premixed Liquid Solution Parsippany, NJ – November 29, 2017 – The U.S. Food…
PARSIPPANY, NJ (October 30, 2017) – Today Ferring Pharmaceuticals announced results from MEGASET HR, a 620 patient, prospective study comparing…
PARSIPPANY, N.J., August 29, 2017 – Ferring Pharmaceuticals announced today that it will donate $25,000 to help the people and…
PARSIPPANY, N.J., June 1, 2017 – Ferring Pharmaceuticals announced today that Paul Navarre has been appointed Chief Executive Officer of…
Saint-Prex, Switzerland – 1 June 2017 – Ferring Pharmaceuticals announced today that Aaron Graff has been appointed Executive Vice President…